Screener
Hemab Therapeutics Holdings, Inc. COAG Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs of $29.6 million | 317,165 | - |
| Principal payments on finance lease | (46) | (59) |
| Net cash provided by (used in) financing activities | 317,119 | (59) |
| Effect of foreign exchange rate changes on cash and cash equivalents | (222) | - |
| Net increase (decrease) in cash and cash equivalents | 149,392 | (12,917) |
| Cash and cash equivalents at beginning of period | 87,974 | 74,407 |
| Cash and cash equivalents at end of period | $237,366 | $61,490 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s financing cash flow?
- Hemab Therapeutics Holdings, Inc. (COAG) reported financing cash flow of $317.58M in Q2 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude